A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.

计划入组 150 人 · 首次发布于 2025 年 9 月 4 日

Skin Testing With Recombinant Bet v 1 and Hypoallergenic Recombinant Bet v 1 Fragments

计划入组 30 人 · 首次发布于 2014 年 3 月 28 日

Immune Response of Individuals Vaccinated With Hypoallergenic Derivatives of the Major Birch Pollen Allergen, Bet v 1

计划入组 20 人 · 首次发布于 2011 年 5 月 16 日

Birch pollen allergen product (Stallergenes Greer)

rBet-v-1 derivatives (Vienna University)

Recombinant birch pollen allergoid (Allergopharma)

NHI-1

United States

UNIVERZA V MARIBORU

Slovenia

Deutsche Lungenstiftung e. V.

Germany

Mabylon Raises CHF 30 Million to Advance Tri-Specific Peanut Allergy Antibody MY006 Through Phase I Trials

Intranasal Monoclonal Antibody Therapy Shows Promise Against Mugwort Pollen Allergy in Preclinical Study

ZYRTEC Launches Drug-Free Allergen Shield Spray for Proactive Allergen Defense